DP
HRMY icon

Diadema Partners’s Harmony Biosciences HRMY Stock Holding History

Diadema Partners’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,100
Closed -$1.38M – 164
2025
Q3 		$1.38M Buy
+50,100
New +$1.73M 0.35% 75

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Diadema Partners's HRMY Position: Q1 2026 in Review

Diadema Partners increased its Harmony Biosciences (HRMY) stake by 1,138% in Q1 2026, buying an estimated $2.8M and bringing the position to 92,864 shares worth $2.6M. The position accounts for 0.44% of the portfolio, ranked #52.

Diadema Partners first reported a position in HRMY in Q3 2025 and has held it in 3 quarters since. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Diadema Partners held 92,864 shares of Harmony Biosciences worth $2.6M as of Q1 2026.
  • Diadema Partners bought 85,364 Harmony Biosciences shares in Q1 2026, an estimated $2.8M.
  • Harmony Biosciences made up 0.44% of Diadema Partners's portfolio in Q1 2026, its #52 holding.
  • Diadema Partners first reported a position in Harmony Biosciences in Q3 2025 and has held it in 3 quarters since.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.